empagliflozin
Boehringer Ingelheim,eli lilly
[]
exciting.. another positive trial for patients with #hfpef. 18% significant reduction in risk of cv-death or worsening hf. like emperor-preserved all driven by worsening hf. is reduction of worsening hf alone good enough to make sglt2 the new standard of care? #esccongress 
NIHR Academic Clinical Fellow in Cardiology. Lover of all things heart related.